FDA approves expanded use of Daytrana
DUBLIN The Food and Drug Administration has approved a drug made by Shire for treating attention deficit hyperactivity disorder in adolescents, Shire said Tuesday.
The FDA approved Daytrana (methylphenidate), a transdermal patch for treating ADHD in adolescents ages 13 to 17 years. The drug already had approval for treating ADHD in children ages 6 to 12 years.
“The FDA approval of Daytrana for adolescents now extends this medication option to an additional group of ADHD patients who may benefit from ADHD treatment delivered by a patch,” Shire SVP for the ADHD business unit Mike Yasick said. “This approval reinforces Shire’s commitment to providing a varied and comprehensive portfolio of medicines to meet he diverse needs of ADHD patients.”
Target gets set to open in East Harlem
MINNEAPOLIS Target announced that it will open its first store on the island of Manhattan in East Harlem on July 25.
According to the company, the store features more space devoted to fresh food, everyday essentials and home basics geared for apartment living. The store is easily accessible with a pedestrian bridge linking mass transit to the store on the second floor of the East River Plaza. A parking deck is also available.
The retailer also said it has tailored the store’s merchandise to reflect the culture of the community. As such, Target said the Harlem store will offer Spanish-language books and movies, multicultural dools and Gospel and Latin music.
As with all Target stores, the new general merchandise store will offer everyday essentials, household products, electronics, clothing and seasonal items. And, it will feature Target’s new expanded food layout offering fresh packaged produce, meats and baked goods, the company reported.
FDA approves expanded use of Infergen
WARRENDALE, Pa. The Food and Drug Administration has approved a new use for a hepatitis C drug made by Three Rivers Pharmaceuticals, the drug maker said Friday.
The FDA approved Three Rivers’ Infergen (interferon alfacon-1) combined with ribavirin for daily treatment of hepatitis C in patients who have failed to respond to pegylated interferon combined with ribavirin.
The approval is based on a late-stage clinical study showing that the combination of Infergen and ribavirin rendered the virus undetectable, also known as sustained virological response.